Theravance's TD-9855 improves symptom severity in Phase II for hypotension

Theravance Biopharma Inc. (NASDAQ:TBPH) reported data from 16 patients with symptomatic neurogenic orthostatic hypotension in Part C of a Phase II trial

Read the full 221 word article

User Sign In